Have a personal or library account? Click to login
RFWD3 Knockdown Inhibits Cancer Cell Proliferation, Migration, and Invasion while Promoting Apoptosis of Non-Small Cell Lung Cancer Cells Cover

RFWD3 Knockdown Inhibits Cancer Cell Proliferation, Migration, and Invasion while Promoting Apoptosis of Non-Small Cell Lung Cancer Cells

By: Ting Ma and  Baolan Wang  
Open Access
|Jun 2025

Abstract

RING finger and WD repeat domain 3 (RFWD3) expression is elevated in various tumor types, but its precise role in non-small cell lung cancer (NSCLC) remains unclear. This study aims to investigate the biological function of RFWD3 in NSCLC and the associated molecular pathways. RFWD3 expression was knocked down in NSCLC cells through transfection. Cell apoptosis was analyzed using flow cytometry, cell viability was assessed using the cell counting kit-8 (CCK-8), and the migration and invasion of NSCLC cells were evaluated using Transwell chamber assays. Additionally, the expression of BAX, BCL-2, cleaved-caspase-3, and key signaling molecules involved in the ERK/p38 pathway was determined using Western blotting. The expression of RFWD3 was found to be elevated in NSCLC cells compared with normal lung epithelial BEAS-2B cells. Its knockdown led to reduced cell proliferation, migration, and invasion and increased apoptosis rate, partially through the inhibition of the ERK/p38 signaling pathway. Knockdown of the RFWD3 gene inhibited NSCLC cell proliferation, migration, and invasion while also inducing apoptosis. These effects are partially attributed to the blockade of the ERK/p38 signaling pathway.

Language: English
Submitted on: Feb 20, 2025
Accepted on: Apr 15, 2025
Published on: Jun 17, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Ting Ma, Baolan Wang, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.